anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an extraction method of coumarin of dahurian angelica root. The extraction method comprises the following steps of carrying out ethanol-based heating backflow extraction on dahurian angelica root, carrying out filtration, carrying out condensation, carrying out alcohol precipitation on the concentrate, carrying out volume metering by water, carrying out extraction by petroleum ether, carrying out extraction by chloroform, recovering the chloroform and carrying out condensation drying to obtain coumarin of dahurian angelica root. The extraction method of coumarin of dahurian angelica root is a simple and fast method. The extraction method utilizes ethanol as a solvent and ethanol is cheap and nontoxic. After extraction, chloroform can be removed by a simple method. Through the extraction method, the extract has dahurian angelica root coumarin content more than 50%. The extraction method has good reappearance and realizes recycle of a solvent. The extracted coumarin of dahurian angelica root is used in spraying agent preparation. An external medicinal spraying agent (such as a compound agent, aerosol and a spraying agent) is prepared from coumarin of dahurian angelica root, kusnezoff monkshood root, acutangular anisodus root, rhizoma arisaematis, safflower, radix lithospermi, benzoin and remote lemongrass herb as raw materials. The external medicinal spraying agent has function of promoting blood circulation to dissipate stasis and dredging collaterals to relieve pain and can be used for treating soft tissue sprain, traumatic injury and joint pain.
BACKGROUND: The spontaneous rupture of an artery aneurysm during the perinatal period is considered a serious complication associated with the physiological alteration by pregnancy and delivery. The rupture of an ovarian artery aneurysm is rare and leads to rapid retroperitoneal hemorrhage. Here, we report one case complicated by postpartum hypertensive disorder of pregnancy associated with massive bleeding into retroperitoneal cavity by the spontaneous rupture of ovarian artery aneurysm after caesarean section, and reviewed previous literature.
CASE PRESENTATION: A 41-year-old Japanese woman was referred to our hospital four days after undergoing cesarean delivery because of hemorrhagic shock with abdominal and right flank pain. Contrast-enhanced computed tomography revealed a large retroperitoneal hematoma. Angiography showed a ruptured right ovarian artery aneurysm, anastomosing with a dilated uterine artery. She was successfully treated with transcatheter arterial embolization. She was diagnosed with postpartum hypertensive disorder of pregnancy 3 days after the embolization.
CONCLUSION: The rupture of ovarian aneurysm can occur during the perinatal period, although it has not been widely understood among obstetricians. Multiparity and hypertensive disorder of pregnancy might be risk factors for the rupture of an ovarian aneurysm. Early diagnosis and therapy, such as transcatheter arterial embolization in preparation for an emergency laparotomy, are crucially important for the management of this fatal disease.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use having excellent preventing effects on skin aging, reducing effects on skin roughening and humectant effects by including a lignan glycoside and a cell activator and/or a humectant. SOLUTION: This skin preparation for external use is obtained by including a lignan glycoside of the formula [R1 and R2 are each glycosyl; (a), (b) and (c) are each 0 or 1] and a cell activator and/or a humectant as active ingredients. The lignan glycoside is a hydrous lower alcohol extract from a sesame seed, a humidified substance thereof, a germinated substance thereof, a pulverized substance or a defatted substance thereof. Deoxyribonucleic acid, adenosine triphosphate, a deproteinized serum extract, a rosemary extract, etc., are used as the cell activator, and chondroitin sulfate, collagen, etc., are used as the humectant. In the case of combined use of the cell activator, the preparation has stable and excellent preventing actions on skin aging. Thereby, the tensity and luster of the skin are maintained and preventing effects on wrinkles are manifested.  When the humectant is used therewith, the preparation is effective in preventing dullness, etc., of the skin from occurring and reduction thereof.
PURPOSE:To immediately know the condition of a hospital or the contents of treatment and to eliminate the necessity of excess inspection or photographing by unitarily managing all medical pictures related to respective patients by one storing medium. CONSTITUTION:The patient receives one storing medium 51 at the hospital and goes to a consultation department. When the patient hands the carried storing medium 51 over to a doctor, the doctor mounts the medium 51 onto a medical picture input / output device 21 and knows the passage of the patient by reading out clinical record information. Next, when the patient comes to the hospital for CT scan on that day, the patient is instructed to go to a radiographic department while carrying the storing medium 51, and a picture is written from a medical picture generating means 13 to the medium 51 by a medical picture input device 11 and an external storage device 12 connected to the input device 11. The patient goes back to the consultation department again while carrying the medium 51, to which the picture is written, and the doctor executes diagnosis according to the CT picture while operating the medical picture input / output device 21, writes the picture into the storing medium as the clinical record information by a medical picture reading means 23 and simultaneously instructs a prescription. Thus, it is not necessary to execute excess inspection or photographing.
The invention relates to a dosage form time-lagged of drugs for therapy of insomnia. Thedosage form comprises a layer or a coating wrapping a matrix containing drug substance sheet cores. The dosage formis adapted to release said drug substance after a lag time during which substantially no drug substance is released. The lag time is about at least one hour after administration of the dosage form. The coating contains less than 10% expandable or jellous materials, and the expandable or jellous materials do not form gel which has release control action. A sustained releasing excipient is provided in the matrix. The drug substance is dissolved or dispersed in the matrix.
A plastic composition for taking dental impressions comprises a gel-forming component, or a mixture of gel-forming components, selected from a water-soluble alginate, a gellable pectin material, and sodium, potassium, or ammonium carboxymethyl cellulose, a metallic salt component, e.g. calcium sulphate, reactive with the gel-forming component or mixture in solution to form an elastic gel, and zinc fluoride uniformly distributed within the composition so that when a plaster cast is made of a dental impression formed in the surface of the composition, the zinc fluoride facilitates the formation of a hard plaster surface.  The metallic salt may comprise calcium sulphate decahydrate, dihydrate or hemi-hydrate, or lead monosilicate, disilicate, basic sulphate, basic carbonate or other lead salt, or a salt of zinc or strontium.  To retard the reaction between the gel-forming component and the metallic salt the composition may contain, either singly or in admixture, sodium carbonate, an alkali metal phosphate or polyphosphate, e.g. trisodium phosphate or polyphosphate or sodium ortho-, meta-, or pyrophosphate, or a metal salt of a tetracarboxy acid of ethylene diamine, as described in U.S.A. Specification 2,657,971.  The composition may also include a filler such as powdered talc, clay, diatomaceous earth, calcium carbonate or silica.ALSO:A plastic composition for taking dental impressions comprises a gel-forming component or a mixture of gel-forming components selected from a water-soluble alginate, a gellable faction material, and sodium, potassium, or ammonium carboxy methyl cellulose, a metallic salt component, e.g. calcium sulphate reactive with the gel-forming component or mixture in solution to form an elastic gel, and zinc fluoride uniformly distributed within the composition, so that when a plaster cast is made of a dental impression formed in the surface of the composition the zinc fluoride facilitates the formation of a hard plaster surface. The gel-forming component is preferably sodium or potassium alginate, and the metallic salt may comprise calcium sulphate, decahydrate, dihydrate, or hemi-hydrate, or lead monosilicate, disilicate, basic sulphate, or basic carbonate, or other lead salt, or a salt of zinc or strontium.  To retard the reaction between the gel-forming component and the metallic salt the composition may contain, either singly or in admixture, sodium carbonate, an alkali metal phosphate or polyphosphate, e.g. trisodium phosphate or polyphosphate, or sodium ortho, meta or pyrophosphate, or a metal salt of a tetracarboxy acid of ethylene diamine as described in U.S.A. Specification 2,657,971.  The composition may also include a filler such as powdered talc, clay, diatomaceous earth, calcium carbonate, or silica.  In an example 0.5 gm. of zinc fluoride is added 72 gm. alkali metal alginate, 220 gm. diatomaceous earth, 7 gm. tetrasodium pyrophosphate and 40 gm. calcium sulphate hemi-hydrate.
There is limited literature regarding wing tip edema (WTE) in raptors, and much of our current understanding of the condition is based on anecdotal reports. The aims of this retrospective study were to describe the clinical features of WTE in birds of prey, to identify prognostic factors for return to flight and patient survival following diagnosis, and to develop and assess the clinical significance of a novel WTE grading system. Between 2004 and 2022, 41 cases of WTE were identified in 39 captive birds. No cases were found in wild birds. Harris's hawks (Parabuteo unicinctus), lanner falcons (Falco biarmicus), and peregrine falcons (Falco peregrinus) had the highest frequencies of WTE, and all cases presented between October and May. Increasing days of air frost per month and colder median monthly temperatures were significant risk factors for the development of WTE. Of the cases where patient outcomes were known, 23/31 (74.2%) cases returned to normal flight and 29/34 (85.3%) cases survived. End-stage disease, represented by primary flight feather loss and metacarpal ischemic (dry) gangrene, and enalapril use were associated with poor patient outcomes. Presentation within 24 hours of disease onset, isoxsuprine use, and physiotherapy were associated with improved patient outcomes. This study showed that WTE is an infrequently encountered but clinically significant condition in captive raptors and is associated with an overall high morbidity and moderate mortality risk.
UNLABELLED: ABASTRACT Background: To study the association between pain and depression, its characteristics and related factors in chilean older adults.
METHODS: Cross-sectional analytical study of the National Survey of Dependence in Chilean older adults 2009, with a sample of 4766 people aged 60 years and older. Pain was described using a Likert scale from "no pain" to "very much pain". Depression was measured using the GDS-15 scale. Adjusted logistic regression analyses were performed to identify the association between pain and depression.
RESULTS: 70% of the sample reported pain, 21.6% of high intensity. The screening was positive for depression in 23% of the sample, and 5% suspected severe depression. Both conditions were more frequent in women, subjects with low levels of schooling and rural residence. There was an association between pain and depression OR 3.46. The greater the intensity of pain, the greater the association OR 5.2 (95% CI 4.1-6.7) for depressive symptoms and OR 13.9 for suspected severe depression (95% CI 8.1-23.9).
CONCLUSION: The association between pain and depression is high and is related to pain intensity, being higher in people with less education and physical dependency. The high frequency of both conditions in Chilean elderly people and their serious consequences make it an urgent public health problem, aggravated as a consequence of the prolonged isolation due to the COVID-19 pandemic.
Systems, methods, and computer-readable media for associating one or more prior therapies with one or more current therapies for a patient are provided. One or more therapies a patient was taking or prescribed prior to visiting a current care venue are accessed. One or more therapies the patient is taking or has been prescribed at the current care venue for the current care venue visit are accessed. Input is received that one of the one or more prior therapies for the patient corresponds with one of the one or more current therapies for the patient. In response to receiving the input, the prior therapy is associated with the current therapy. The association of the corresponding prior therapy and the corresponding current care venue therapy is stored for the patient.
An improved method of inducing protective immunity to the Human Immunodeficiency Virus through isolating a person's antigen-presenting cells from blood, then pulsing these cells with short peptides that bind the person's Class I Major Histocompatibility Complex Types and correspond to conserved segments of the HIV structural and functional genes. These pulsed dendritic cells are then injected intravenously, where they will travel to lymph tissue and prime HIV-specific Cytotoxic T Lymphocytes. The immune system is then activated by injecting the person with a weakened arbovirus, Chikungunya. The interferons and other immune-activating chemicals induced by the virus will stimulate creation of billions of killer cells that recognize HIV proteins, allowing for rapid mobilization of memory immune cells to contain and eliminate any subsequent infection with the HIV virus. The vaccine is custom-designed to each person and uses no HIV virus for safety purposes. It is understood that the examples an embodiments described herein are for illustrative purposes only and various changes or modifications in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.
The stimulation will be delivered over the motor cortex contralateral to the predominant painful region, i.e., right motor cortex stimulation if left knee pain. The stimulation intensity will be set at 80% of the resting motor threshold.
Ductal carcinoma in situ (DCIS) represents 18% to 25% of all diagnosed breast cancers, and is a noninvasive, nonobligate precursor lesion to invasive cancer. The diagnosis of DCIS represents a wide range of disease, including lesions with both low and high risk of progression to invasive cancer and recurrence. Over the past decade, research on the topic of DCIS has focused on the possibility of tailoring treatment for patients according to their risk for progression and recurrence, which is based on clinicopathologic, biomolecular and genetic factors. These efforts are ongoing, with recently completed and continuing clinical trials spanning the continuum of cancer care. We conducted a review to identify recent advances on the topic of diagnosis, risk stratification and management of DCIS. While novel imaging techniques have increased the rate of DCIS diagnosis, questions persist regarding the optimal management of lesions that would not be identified with conventional methods. Additionally, among trials investigating the potential for omission of surgery and use of active surveillance, 2 trials have completed accrual and 2 clinical trials are continuing to enroll patients. Identification of novel genetic patterns is expanding our potential for risk stratification and aiding our ability to de-escalate radiation and systemic therapies for DCIS. These advances provide hope for tailoring of DCIS treatment in the near future.
Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
Nicotine ion pair formulations neutralized with CO2 are disclosed herein. The nicotine ion pair formulations have the general formula C10H14N2H+CO2Sol, wherein C10H14N2 is nicotine and Sol is a solvent. A process of preparing the nicotine ion pair formulations neutralized with CO2. is also disclosed herein. An e-liquid comprising a nicotine ion pair formulation neutralized with CO2 and the use of the e-liquid in a vaporization device are further disclosed herein. Finally, a vaporization device charged with an e-liquid comprising a nicotine ion pair formulation neutralized with CO2 is disclosed herein.
Arthroscopic surgery for cartilage and meniscus injuries are some of the most common orthopaedic procedures currently performed. Post-surgical pain is initiated through an inflammatory response to surgery. The pain response leads to sleep disruption and a further increase in pain and additional sleep disruption. Opioid medications are often used after surgery to treat pain despite the side effect profile. These medications also contribute to poor sleep quality and duration. Early pain and narcotic use can be controlled by mitigating the effects of post-surgical inflammation. Ceftriaxone is a readily available antibiotic and may have the desirable anti-inflammatory and analgesic effects, but without the side effects caused by other medications. Since it is highly selective in its inhibition, ceftriaxone is an excellent candidate for reducing immediate post-operative pain and heightened inflammatory response.

By doing this study, the investigators hope to learn about the anti-inflammatory effectiveness of the antibiotic ceftriaxone. Ceftriaxone has been shown to inhibit a key enzyme in the post-operative inflammatory process and has been safely used for treatment of infections for years. The investigators would like to gather information about whether ceftriaxone helps reduce pain and inflammation after surgery. Participation in this research will last about 2 months.
Tolcapone pharmacokinetics are independent of sex, age, body weight, and race (Japanese, Black and Caucasian). Polymorphic metabolism is unlikely based on the metabolic pathways involved.

###  Hepatic Impairment:

A study in patients with hepatic impairment has shown that moderate non-cirrhotic liver disease had no impact on the pharmacokinetics of tolcapone. In patients with moderate cirrhotic liver disease (Child-Pugh Class B), however, clearance and volume of distribution of unbound tolcapone was reduced by almost 50%. This reduction may increase the average concentration of unbound drug by twofold (see DOSAGE AND ADMINISTRATION). Tolcapone tablets therapy should not be initiated if the patient exhibits clinical evidence of active liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal (see BOXED WARNING).

###  Renal Impairment:

The pharmacokinetics of tolcapone have not been investigated in a specific renal impairment study. However, the relationship of renal function and tolcapone pharmacokinetics has been investigated using population pharmacokinetics during clinical trials. The data of more than 400 patients have confirmed that over a wide range of creatinine clearance values (30 mL/min to 130 mL/min) the pharmacokinetics of tolcapone are unaffected by renal function. This could be explained by the fact that only a negligible amount of unchanged tolcapone (0.5%) is excreted in the urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile. Accumulation of this stable and inactive metabolite should not present a risk in renally impaired patients with creatinine clearance above 25 mL/min (see DOSAGE AND ADMINISTRATION). Given the very high protein binding of tolcapone, no significant removal of the drug by hemodialysis would be expected.

###  Drug Interactions:

See PRECAUTIONS: Drug Interactions.
Relating to microorganism fermented Chinese medicinal poultry drugs, the invention provides a production method for a lactic acid bacteria fermented poplar flower oral liquid. The method includes: taking 80-100mL of poplar flower water, 3-5g of soybean meal, 3-5g of brown sugar and 1.5-2.5g of peptone; coordinating the raw materials, conducting high-pressure sterilization, inoculating lactic acid bacteria accounting for 1% of the weight of the raw materials, and carrying out anaerobic fermentation at 37DEG C for 48h, thus obtaining the oral liquid. According to the invention, lactic acid bacteria are employed to ferment poplar flower water, at the end of fermentation, the fermentation broth contains two effective ingredients, i.e. lactic acid bacteria and fermentation type poplar flower extract. During application, the product can give play to the intestinal flora regulating, animal immunity enhancing and pathogenic microorganism inhibiting effects of lactic acid bacteria, and also can bring the poplar flower's efficacy of tonifying spleen and nourishing stomach, resolving dampness and stopping dysentery, relieving diarrhea with astringents, clearing away heat and toxic materials into play. Also, after fermentation in vitro, poplar flowers are easier to absorb, thereby better achieving the treatment purpose. The drug involved in the invention has the advantages of treatment of both symptoms and root causes, rapid efficacy, pure green and no residue, and excellent curative effect. 167 cases of clinical tests show that the total effective rate reaches 97.0%.
Caution in handling the solution must be exercised as skin reactions associated with IDAMYCIN PFS may occur. Skin accidentally exposed to IDAMYCIN PFS should be washed thoroughly with soap and water and if the eyes are involved, standard irrigation techniques should be used immediately. The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.

Care in the administration of IDAMYCIN PFS will reduce the chance of perivenous infiltration. It may also decrease the chance of local reactions such as urticaria and erythematous streaking. During intravenous administration of IDAMYCIN PFS extravasation may occur with or without an accompanying stinging or burning sensation even if blood returns well on aspiration of the infusion needle. If any signs or symptoms of extravasation have occurred, the injection or infusion should be immediately terminated and restarted in another vein. If it is known or suspected that subcutaneous extravasation has occurred, it is recommended that intermittent ice packs (1/2 hour immediately, then 1/2 hour 4 times per day for 3 days) be placed over the area of extravasation and that the affected extremity be elevated. Because of the progressive nature of extravasation reactions, the area of injection should be frequently examined and plastic surgery consultation obtained early if there is any sign of a local reaction such as pain, erythema, edema or vesication. If ulceration begins or there is severe persistent pain at the site of extravasation, early wide excision of the involved area should be considered.

IDAMYCIN PFS should be administered slowly (over 10 to 15 minutes) into the tubing of a freely running intravenous infusion of Sodium Chloride Injection, USP (0.9%) or 5% Dextrose Injection, USP. The tubing should be attached to a Butterfly needle or other suitable device and inserted preferably into a large vein. IDAMYCIN PFS is provided in single dose vials. Discard unused portion.
Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.